- Austrian researchers report CBD reduces inflammation and speeds recovery in ICU COVID-19 patients
- Research suggests CBD’s anti-inflammatory properties stave off long-term neurological damage associated with COVID-19
- PACR leverages genetic technology to produce potent CBD strains with higher yields per growing season
- Company catalog includes 350 cultivars and 50 super-elite strains prized in industry
CBD may soon become the newest support in the world’s fight against COVID-19: Researchers at the Klagenfurt Clinic in Austria recently reported positive results from cannabidiol (“CBD”) trials on COVID-19 patients that demonstrated reduced inflammation and quicker recovery times (https://cnw.fm/gUeyW). Pac Roots Cannabis (CSE: PACR) (OTCQB: PACRF), a Canada-based cannabis company dedicated to producing premium-quality strains and products through a genetics-focused approach, leverages genetic technology to cultivate unique strains prized in the industry for their potency and overall effectiveness.
CBD continues to gain mainstream attention among healthcare professionals and the general public as a way to address symptoms of chronic diseases – particularly those associated with inflammation (https://cnw.fm/2v5tD). Accordingly, researchers at the Klagenfurt Clinic in Austria used CBD oil to treat COVID-19 ICU patients for three weeks and observed positive changes in inflammation markers throughout the treatment.
“We have seen that the inflammation parameters in the blood go down, and people leave the hospital faster than the comparison group,” said Rudolf Likar, head of intensive care medicine at the clinic. “CBD supports the immune system. We’ll probably use this routinely now because it doesn’t have any side effects.”
According to the researchers, CBD’s anti-inflammatory effects surpassed those of other commonly used drugs because of its ability to easily cross the blood-brain barrier and stave off some of the long-term neurological damage associated with the disease.
PACR’s genetics-based approach to cannabis cultivation has produced roughly 350 tested cultivars, including 50 super-elite strains with varying amounts of tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”) – two of over 140 known cannabinoids in the cannabis plant that can produce different effects on the body. The Company also uses genetic technology to optimize its cultivars to produce maximum yields according to varying climatic conditions and growing seasons with the potential to boost profit margins through reduced labor costs and increased output.
A critical competitive advantage that sets PACR apart is its strategic licensing agreement with Phenome One Corp – a privately-held full-service genetics cannabis company that gives PACR access to one of Canada’s largest living genetic cannabis libraries. Along with giving its partners access to a massive database of detailed information, Phenome One also subjects each cultivar to rigorous analysis and testing—a process that goes back more than 30 years.
The growing body of scientific evidence supporting the use of CBD along with increasingly relaxed laws around the use of cannabis is contributing to the ever-increasing market opportunity for cannabis cultivators. PacRoots Cannabis Corp. appears to be favorably positioned to benefit from the explosive growth in demand for their first-in-class high-yield strains that appeal to a wide variety of consumers across the rapidly growing legal cannabis market.
For more information, visit the company’s website at www.PacRoots.ca.
NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://cnw.fm/PACR
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire is part of the InvestorBrandNetwork.